Warning letter
Sato Pharmaceutical Co., Ltd.: warning letter of May 18, 2026
FDA warning letter 723059 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 723059 |
|---|---|
| Company | Sato Pharmaceutical Co., Ltd. |
| Subject | CGMP/Drugs/Adulterated/OTC |
| Issue date | May 18, 2026 |
| Posted date | May 26, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.165(b), 211.34, 211.113(b), 211.160(b), 211.166(a) |
| Inspection city | Hachioji |
| Inspection start date | Nov 13, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: